AtriCure to Present at the 9th Annual JMP Securities Healthcare Conference

  AtriCure to Present at the 9th Annual JMP Securities Healthcare Conference  JMP Securities Healthcare Conference 2014  Business Wire  WEST CHESTER, Ohio -- May 28, 2014  AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the 9^th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Tuesday, June 24, 2014. Management is scheduled to present at1:30 p.m. Eastern Time.  A live audio webcast and replay of the presentation will be available for 90 days following the presentation at  About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide.The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.  Contact:  AtriCure, Inc. Andy Wade, Vice President and Chief Financial Officer, 513-755-4564 or Investor Relations Contact Westwicke Partners Lynn Pieper, 415-202-5678  
Press spacebar to pause and continue. Press esc to stop.